Completed PHASE3 INTERVENTIONAL 3-arm NCT03386032

8-Week Atopic Dermatitis (AD) Treatment Study

Sponsor: Procter and Gamble

Interventions 0.05% Desonide Investigational OTC Cream Placebo Cream

Updated 6 times since 2018 Last updated: Dec 15, 2020 Started: Nov 27, 2017 Primary completion: Aug 18, 2018 Completion: Aug 18, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Atopic Dermatitis Eczema, this trial is completed. The trial is conducted by Procter and Gamble and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE3

▶ Show 1 earlier version

Jan 2018 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Procter and Gamble

Data source: Procter and Gamble

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chattanooga, United States
• Raleigh, United States